Preliminary Experience of Routine Voriconazole Therapeutic Drug Monitoring (TDM) in a Tertiary Care Centre

Universitaire Ziekenhuizen KU Leuven160 enrolled

Overview

The first goal of this study is to map all the subtherapeutic, therapeutic and supratherapeutic voriconazole plasma levels in the University Hospitals Leuven. The second objective is to optimize and validate guidelines for dose modifications in patients with too low or high plasma concentrations and to investigate if the same guidelines can be used in different patient populations.

Study Type

OBSERVATIONAL

Enrollment

160

Conditions

Patients Treated With Voriconazole

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients treated with voriconazole * at least 1 voriconazole plasma level measured during therapy Exclusion Criteria: * none

Locations (1)

University Hospitals Leuven

Leuven, Vlaams-Brabant, Belgium

Outcomes

Primary Outcomes

Voriconazole plasma levels during routine intravenous and oral therapy

Time frame: trough levels every 4 days after start or dose adjustment of voriconazole

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.